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Abstract  
This study estimates the cost burden of six prevalent invasive cancers—breast, cervical, colorectal, lung, melanoma, and 
prostate—on Medicaid programs in four states. The analyses used Medicaid claims and enrollment data for all Medicaid-only 
beneficiaries over 18-years-old in Georgia, Illinois, Louisiana, and Maine with at least one month of enrollment in fee-for-service 
Medicaid from 2000 to 2003. We applied ordinary least squares regression analysis to a data set created from Medicaid claims and 
enrollment data to estimate annual expenditures attributable to each cancer after controlling for age, race, gender, and comorbid 
conditions. Cancers and comorbid conditions were identified on the basis of claims with an appropriate diagnosis code. In 2003 
dollars, annualized Medicaid expenditures attributable to the six cancers combined in the Medicaid-only population were $84.0 
million in Georgia, $79.7 million in Illinois, $51.4 million in Louisiana, and $29.4 million in Maine. Attributable annualized 
per-capita Medicaid expenditures were highest for lung cancer, then colorectal cancer. After adjusting for sociodemographics and 
comorbidities, only 10% to 50% of medical expenditures among Medicaid-only beneficiaries with cancer were attributable to 
cancer. Estimates of the costs of care for Medicaid-eligible cancer patients are critical to understanding the implications of cancer 
for state and federal budgets. The Affordable Care Act of 2010 is expected to substantially expand the adult Medicaid population. 
These estimates provide important baseline information for assessing the potential effects of increased Medicaid enrollment on 
Medicaid expenditures for cancer. 
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Introduction  
The burden of cancer in the United States is 
considerable. More than 1.3 million Americans 
were diagnosed with cancer in 2006
 
[1]. Cancer 
reduces quality of life and it results in substantial 
medical expenditures. From 2001 through 2005, 
cancers cost the United States an estimated $48 
billion in direct medical cost [2]. Previous research 
has quantified the economic burden of cancer [2-8], 
but few studies have examined the burden on 
Medicaid programs [9]. One of the only studies to 
do so estimated that the average annual Medicaid 
expenditures for cancer were $1.6 billion over the 
years 2001 through 2005[2]. However, this study 
did not report costs by cancer site. Although 
annual U.S. cancer expenditures have been 
growing generally, nearly doubling from 1987 to 
the period from 2001–2005, Medicaid expenditures 
for cancer grew more rapidly than did those of 
other payers. Medicaid’s share of total U.S. 
medical expenditures for cancer increased from 1% 
to 3% over this time period [2]. 
This trend will likely accelerate in coming years. 
Under provisions of the Breast and Cervical 
Cancer Treatment Act of 2000, all 50 states and the 
District of Columbia provide Medicaid coverage to 
low-income women who were identified as having 
breast or cervical cancer, including pre-cancerous 
conditions, as a result of testing covered through 
the National Breast and Cervical Cancer Early 
Detection Program [10]. The Affordable Care Act 
(ACA) of 2010, which allows states to expand 
Medicaid coverage to all adults with income up to 
138% of the Federal Poverty Level beginning in 
2014, will likely increase the number of people 
with coverage and therefore the number of people 
diagnosed with cancer and expenditures for cancer 
in state Medicaid programs. Most of this 
enrollment growth will occur among adults, which 
will shift the age distribution of the Medicaid 
population away from children (currently about 
half of the Medicaid population [11]) to age groups 
where cancer is more prevalent. 
This study quantifies the economic cost of six 
invasive cancers-breast, cervical, colorectal, lung, 
melanoma, and prostate-on Medicaid programs in 
four states. To differentiate costs attributable to 
cancer from those attributable to comorbid 
conditions, we estimate costs using multivariate 
regression modeling analysis. This methodology 
can be used to develop estimates for other states, 
based on Medicaid claims and enrollment data. 
The increasing cost of cancer treatment 
(especially chemotherapy), the fact that many 
cancer control efforts are funded at the state or 
local level, and the expanding role of Medicaid in 
providing cancer care to low-income, uninsured 
individuals have created an urgent need to 
understand the economic burden of cancer to state 
Medicaid programs
 
[2, 12]. Previous studies of 
cancer costs using other sources such as Medicare 
or health maintenance organization (HMO) data 
may not be relevant to Medicaid, given differences 
in reimbursement rates, treatment intensity, tumor 
sites, sociodemographics, stage at diagnosis, and 
comorbidity prevalence for these groups
 
[13]. 
Estimates of current Medicaid spending for cancer 
provide a baseline for projecting the additional 
cost of paying for cancer care in Medicaid 
programs as a result of increased enrollment in 
Medicaid and valuable information for 
policymakers considering policies to reduce cancer 
prevalence and cancer treatment costs. 
Materials and Methods 
The analyses used Medicaid Analytic eXtract 
(MAX) data for four states: Georgia, Illinois, 
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Louisiana, and Maine. MAX is a uniform dataset 
containing Medicaid eligibility, utilization, and 
payment information that is created by the Centers 
for Medicare and Medicaid Services (CMS) from 
Medicaid Statistical Information System data 
submitted by the states [14]. This study used 
2000–2003 data, which were the most current 
years available when the study began. As 
enrollment in Medicaid managed care has grown 
over time, it has become increasingly difficult to 
identify states where the proportion of the 
population with fee-for-service claims is large 
enough to be considered representative.  
The study states were selected because they 
enrolled a low percentage of the Medicaid 
population in capitated managed care plans. 
Although states are required to report encounter 
data for utilization by enrollees in capitated 
managed care plans, CMS does not recommend 
using encounter data for statistical analyses 
because reporting is incomplete and the accuracy 
of the reported encounter data is not validated [15]. 
The four study states enrolled less than 10% of 
their Medicaid beneficiaries in capitated managed 
care plans during the study years. 
The study population included 100% of 
Medicaid-only beneficiaries who were over age 18, 
were residing in the study states, and had at least 
one month of enrollment in fee-for-service 
Medicaid during the 4-year period. Beneficiaries 
who were dually eligible for Medicare were 
excluded because Medicare, rather than Medicaid, 
covers the majority of their health care 
expenditures. We included part-year enrollees 
because they are a significant portion of the 
Medicaid population; excluding them could bias 
estimates if they differ systematically from 
full-year enrollees. All analyses were weighted by 
months of Medicaid enrollment. Eligibility and 
utilization data for periods of enrollment in 
capitated managed care were excluded from the 
analyses. 
We first calculated mean expenditures per state 
for persons with breast, cervical, colorectal, lung, 
melanoma, and prostate cancer and all other 
beneficiaries, including those with cancers not 
included in our study. We then used multivariate 
regression to estimate marginal expenditures 
attributable to each study cancer after controlling 
for sociodemographics and comorbidities. All 
analyses were conducted with SAS software, 
version 9.2 (SAS Institute Inc., Cary, NC). 
We classified a beneficiary as having one of the 
six study cancers if an International Classification 
of Diseases, 9th Revision, Clinical Modification 
(ICD-9-CM) diagnosis code for that type of cancer 
was in any inpatient Medicare or Medicaid claim 
for that beneficiary or in at least two claims on 
different dates for any other type of service for that 
beneficiary (A complete list of diagnosis codes for 
the study cancers is available from the authors on 
request). The requirement of at least two claims in 
outpatient settings, which avoids including 
individuals with a visit to rule out a cancer 
diagnosis, has been used in previous claims-based 
estimates of prevalence costs of care for cancer 
patients [16]. Because we are unable to identify 
date of cancer diagnosis, beneficiaries identified as 
having cancer include both incident and prevalent 
cases. Therefore, our cost estimates include 
individuals who may no longer be receiving active 
treatment for their cancer.  
We used ordinary least squares multivariate 
regression to estimate annualized per-capita 
Medicaid expenditures attributable to the six study 
cancers. Although non-linear two-part models are 
often used to model health care expenditures to 
account for the large percentage of individuals that 
do not use services, as well as skewness in the 
distribution of expenditures among service users, 
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ordinary least squares has been used by previous 
studies to predict annual medical costs [17, 18], 
particularly in analyses such as the present study 
with a very large number of observations.  
Unlike other commonly used methods to 
estimate disease costs, these analyses did not use 
diagnosis or procedure codes to identify individual 
cancer-related claims. Instead, the attributable cost 
of each cancer was calculated as the difference in 
predicted total Medicaid expenditures with and 
without that cancer holding all other variables in 
the regressions constant at their mean level. The 
regression approach minimizes attributing the 
same medical expenditures to more than one 
disease by controlling for other diseases for people 
with co-occurring diseases [19,20].  
The regression model included variables 
indicating whether the individual had each of the 
six study cancers. In addition, the regressions 
included controls for age (expressed as a 
continuous variable), age squared (to allow for 
non-linear effects of age), gender (male, with 
female omitted), race (black, Hispanic, and other, 
with white omitted), and the presence of 25 
selected potentially costly or prevalent diseases 
and medical conditions. These included 
non-studied cancers, carcinoma in situ, diabetes, 
hypertension, congestive heart failure, stroke, 
coronary heart disease, other cardiovascular 
diseases, asthma, back problems, chronic 
obstructive pulmonary disease, dyslipidemia, 
HIV/AIDS, injuries, pneumonia, pregnancy, renal 
failure, skin problems, arthritis, depression, 
organic psychoses, other mental health or 
substance abuse disorders, mental retardation, and 
degenerative diseases (A list of diagnosis codes for 
comorbid conditions is available from the authors 
on request). Including controls for these diseases 
and conditions prevents attribution of costs of 
co-occurring diseases to the study cancers. 
Procedures comparable to those used to identify 
cancers were used to identify whether an 
individual had each of the 25 comorbid conditions.  
The dependent variable in the regression models 
was annualized person-level Medicaid 
expenditures for all services. Payments in 
2000–2002 were inflated to 2003 dollars using the 
medical care Consumer Price Index. Expenditures 
were annualized, based on the number of months 
the beneficiary was enrolled in Medicaid during 
the four years, to adjust for beneficiaries’ various 
lengths of enrollment. We used SAS version 9 to 
conduct the analyses. 
Results  
The final study population sizes were: Georgia (n 
= 683,695), Illinois (n = 953,556), Louisiana (n = 
375,851), and Maine (n = 194,425). Table 1 shows 
the age, race, and gender distribution of the study 
population in the 4 states by whether an individual 
was diagnosed with any of the six study cancers.  
In all four states, Medicaid-only beneficiaries 
with any of the six study cancers were significantly 
older than other beneficiaries (51-55 years-old 
compared with 34-37 years-old) (Table 1). Whites 
comprised a significantly larger percentage of 
those with the six study cancers compared with 
other beneficiaries in all four states. Although 
Medicaid-only beneficiaries (with or without the 
six cancers) were predominantly female, in 
Georgia and Illinois, males were a significantly 
larger proportion of the population with the study 
cancers. 
Medicaid-only beneficiaries with the six study 
cancers were significantly more likely to have a 
variety of comorbidities than other beneficiaries 
(Table 2). Approximately 66% of individuals with 
the six cancers in Georgia, Illinois, and Louisiana, 
and 50% in Maine, had hypertension, which is 
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more than twice the rate for other beneficiaries. 
Other conditions with high prevalence among 
individuals with the study cancers were arthritis, 
mental health and substance abuse disorders, and 
cardiovascular diseases. With the exception of 
pregnancy and mental retardation, Medicaid-only 
beneficiaries with the six study cancers were 
almost always significantly more likely to have 
these comorbid conditions than other beneficiaries, 
generally were two or more times more likely. The 
comparison group includes both individuals 
without cancer and those with non-study cancers. 
However, only about 1% of the comparison group 
has an invasive non-study cancer.  
Table 3 shows the prevalence of the six study 
cancers among all Medicaid-only beneficiaries. We 
report gender-specific prevalence for breast, 
cervical, and prostate cancer. The prevalence of 
breast cancer in the overall Medicaid-only 
population ranged from 5.8 (Maine) to 8.3 
(Louisiana) per 1,000 female enrollees, whereas 
the prevalence of cervical cancer was 2.0-2.9 per 
1,000 women, depending on the state. The 
prevalence of prostate cancer in the overall 
Medicaid-only population varied considerably 
from 1.3 (Maine) to 5.8 (Georgia) per 1,000 male 
enrollees. The prevalence of lung cancer in the 
overall Medicaid-only population was 2.3-3.8 per 
1,000 adult Medicaid-only beneficiaries and 
colorectal cancer was 1.3-2.6 per 1,000. The 
prevalence of melanoma was < 1 per 1,000 adult 
Medicaid-only beneficiaries in all four states. 
Looking across the entire Medicaid-only 
population including both women and men, in all 
four states breast cancer was the most common, 
followed by lung, colorectal, cervical, prostate, 
and melanoma (except in Maine where melanoma 
was more prevalent than prostate cancer) (data not 
shown). 
Individuals with cancer had substantially higher 
Medicaid expenditures than did other beneficiaries, 
including those with non-study cancers (Table 4). 
Depending on the state and cancer site, mean 
annualized Medicaid expenditures per capita were 
3-8 times higher for Medicaid beneficiaries with 
the six study cancers than for other beneficiaries. 
In all four states, lung cancer patients had the 
highest annualized per-capita expenditures, 
ranging from about $31,000 in Louisiana to almost 
$57,000 in Maine. Individuals with colorectal 
cancer had the second highest per-capita 
expenditures in all states, with a low of 
approximately $24,000 in Louisiana and a high of 
about $40,000 in Maine. Mean per-capita 
expenditures were highest in Maine for patients 
with each type of cancer and they were lowest in 
Louisiana, for all cancers except prostate.  
Although Medicaid beneficiaries with cancer 
had substantially higher per-capita annualized 
expenditures than other beneficiaries, their greater 
age and larger number of comorbid conditions may 
be contributing factors. The regression-adjusted, 
annualized per-capita Medicaid expenditures 
attributable to each type of cancer (Table 5) were 
about 10% to 50% of the unadjusted expenditures 
for individuals with these cancers, depending on 
the state and type of cancer.  
Annualized per-capita Medicaid expenditures 
attributable to cancer were highest for lung cancer, 
ranging from about $12,000 in Illinois and 
Louisiana to $29,000 in Maine. Colorectal cancer 
had the next highest attributable annualized 
per-capita expenditures, varying from about $8,000 
in Louisiana to almost $17,000 in Maine. In all 
states, breast cancer had the third highest 
attributable annualized per-capita expenditures, 
ranging from about $4,000 in Illinois to more than 
$12,000 in Maine. With a few exceptions 
(melanoma in Louisiana and melanoma, cervical, 
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and prostate cancers in Illinois), estimated 
annualized per-capita attributable costs were 
significantly different from 0 at P < 0.05 or higher.  
Total regression-adjusted annualized Medicaid 
expenditures attributable to the six cancers are 
shown in Figure 1. Total attributable expenditures 
were highest for lung cancer in all four states, 
ranging from $44 million per year in Illinois, 
which has the largest Medicaid population of the 4 
states, to $15 million in Maine, which as the 
smallest Medicaid population. Except in Illinois, 
breast cancer had the second highest total 
attributable expenditures followed by colorectal 
cancer. Annualized expenditures attributable to 
breast cancer ranged from approximately $29 
million in Georgia to $7 million in Maine. Total 
expenditures attributable to cervical, melanoma, 
and prostate cancer were lower ($5 million or less).
Table 1 Characteristics of Medicaid-only Beneficiaries by State and Cancer Status, Age > 18  
 
 Georgia  Illinois  Louisiana  Maine  
Georgia 
6 Study 
Cancers 
All 
Others†  
6 Study 
Cancers 
All 
Others†  
6 Study 
Cancers 
All 
Others†  
6 Study 
Cancers 
All 
Others†  
Age 
(mean) 
53.1 34.2 *** 54.8 35.8 *** 52.6 34.2 *** 51.4 36.6 *** 
             
Race (%)   ***   ***   ***   ** 
White 41.3 37.8  45.4 39.3  33.4 30.8  97.5 95.9  
Black 44.0 55.8  42.6 41.9  56.1 62.5  0.5 1.5  
Hispanic 0.5 0.7  8.3 14.8  0.6 0.4  0.2 0.4  
Other 14.2 5.7  3.7 4.1  9.9 6.3  1.8 2.1  
             
Sex (%)   ***   ***   ***   *** 
Female 73.1 79.3  70.8 75.0  74.9 72.3  76.9 63.5  
Male 27.0 20.7  29.2 25.1  25.1 27.7  23.1 36.5  
             
N 8,421 675,274  11,862 941,694  5,857 369,994  1,674 192,751  
***Significantly different from beneficiaries with a study cancer at p  < 0.001; **Significantly 
different from beneficiaries with a study cancer at p  < 0.01; 
†
All others includes individuals with 
cancers other than the 6 study cancers. ; Statistical test for age is t -test of difference in means. 
Statistical test for race and sex is chi -square test of difference in distribution.  
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Table 2  Percent of Medicaid-only Beneficiaries with Comorbid Conditions by State and Cancer 
Status, Age > 18 
 
 Georgia  Illinois  Louisiana  Maine  
 
6 Study 
Cancers 
All 
Others†  
6 Study 
Cancers 
All 
Others†  
6 Study 
Cancers 
All 
Others†  
6 Study 
Cancers 
All 
Others†  
Diabetes 23.9 9.9 *** 26.5 10.4 *** 28.3 11.3 *** 20.2 7.0 *** 
Hypertension 64.6 26.7 *** 66.1 25.1 *** 66.1 30.2 *** 50.2 19.9 *** 
Congestive Heart 
Failure 11.4 2.8 *** 16.1 3.4 *** 13.5 3.9 *** 6.7 1.1 *** 
Stroke 6.8 2.0 *** 8.7 2.1 *** 8.0 2.6 *** 3.1 0.8 *** 
Asthma 10.4 5.4 *** 17.7 9.0 *** 10.4 6.1 *** 11.6 6.9 *** 
Back Problems 25.0 12.8 *** 26.7 12.3 *** 21.8 12.9 *** 35.0 19.4 *** 
Chronic Obstructive 
Pulmonary Disease 26.8 5.8 *** 28.6 6.3 *** 25.6 7.8 *** 27.2 5.7 *** 
Depression 17.1 9.9 *** 25.6 14.0 *** 14.7 9.7 *** 29.3 21.1 *** 
Dyslipidemia 13.2 4.8 *** 17.3 6.1 *** 13.2 6.0 *** 18.8 8.0 *** 
HIV/AIDS 2.2 1.3 *** 2.1 1.0 *** 1.4 1.2  0.4 0.2 * 
Injuries 42.2 21.1 *** 46.8 24.0 *** 39.9 24.8 *** 47.1 27.5 *** 
Pneumonia 19.0 3.8 *** 22.1 4.4 *** 19.1 4.3 *** 15.1 2.5 *** 
Pregnancy 4.1 35.9 *** 3.4 30.3 *** 5.8 30.5 *** 4.3 15.6 *** 
Renal Failure 7.3 1.5 *** 8.3 1.6 *** 6.4 1.7 *** 3.0 0.6 *** 
Skin Problems 20.2 10.0 *** 27.4 12.1 *** 24.1 13.4 *** 27.8 12.6 *** 
Arthritis 47.9 21.0 *** 53.4 22.4 *** 46.2 22.9 *** 53.2 27.5 *** 
Mental 
Health/Substance 
Abuse 38.3 19.4 *** 44.5 24.0 *** 29.5 18.1 *** 45.1 33.3 *** 
Organic Psychoses 3.8 1.0 *** 5.4 1.2 *** 2.2 0.8 *** 2.8 0.8 *** 
Mental Retardation 1.5 2.8 *** 1.5 2.0 *** 1.7 2.9 *** 1.4 1.6  
Degenerative Diseases 4.0 1.1 *** 5.4 1.4 *** 2.8 1.1 *** 2.2 0.9 *** 
Coronary Heart 
Disease 14.3 3.5 *** 20.3 4.8 *** 17.1 5.4 *** 10.8 2.6 *** 
Other Cardiovascular 
Diseases 39.1 10.2 *** 45.9 12.4 *** 40.6 13.1 *** 32.9 6.8 *** 
Cancer in situ 15.7 0.6 *** 18.5 0.7 *** 19.4 0.5 *** 22.9 0.8 *** 
Non-melanoma Skin 
Cancer 2.0 0.2 *** 1.4 0.1 *** 1.9 0.1 *** 2.2 0.2 *** 
Other Non-study 
Cancers 15.9 0.9 *** 21.3 1.2 *** 19.3 1.0 *** 16.8 0.8 *** 
***Significantly different from beneficiaries with a study cancer at p  < 0.001; *Significantly different  
from beneficiaries with a study cancer at p  < 0.05; 
†
All others include individuals with cancers other  
than the 6 study cancers.   
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Table 3 Prevalence of Study Cancers per 1,000 Medicaid-only Beneficiaries by State, Age >  18  
 
Cancer Type Georgia Illinois Louisiana Maine 
Breast cancer 
(women only) 
6.8 6.6 8.3 5.8 
Cervical cancer 
(women only) 
2.2 2.8 2.9 2.0 
Colorectal cancer 2.1 2.6 2.6 1.3 
Lung cancer 3.4 3.4 3.8 2.3 
Melanoma 0.4 0.3 0.3 0.7 
Prostate cancer 
(men only) 
5.8 5.6 3.7 1.3 
 
Table 4  Mean Annualized Per-capita Medicaid Expenditures for Medicaid -only Beneficiaries by 
State and Cancer Site, Age >  18 
 
 Georgia Illinois Louisiana Maine 
Cancer 
Site 
Mean 
($) 
Standard 
Deviation ($) 
Mean 
($) 
Standard 
Deviation ($) 
Mean 
($) 
Standard 
Deviation ($) 
Mean 
($) 
Standard 
Deviation ($) 
Breast 20,960 102,415 21,811 166,218 20,784 120,460 28,748 192,692 
Cervical 18,875 100,581 21,663 178,079 14,455 100,136 23,082 254,754 
Colorectal 27,378 129,185 36,501 281,129 24,431 125,534 40,265 310,470 
Lung 32,590 130,848 43,025 278,068 31,229 123,689 56,709 333,576 
Melanoma 21,156 105,296 21,484 180,109 19,031 89,449 22,211 173,996 
Prostate 17,903 100,044 26,397 206,601 18,565 101,612 35,112 285,226 
All Others† 6,150 54,207 7,789 109,828 6,736 70,406 7,070 97,835 
†
All others include individuals with cancers other than the 6 study cancers.  
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Table 5 Annualized Per-capita Cancer Attributable Expenditures for Medicaid-only Beneficiaries by State and Cancer Site,  Age >  18 
 
 Georgia Illinois Louisiana Maine 
Cancer 
Site 
Attributable 
Expenditures  
(Standard Error)($) 
 Percent of 
Mean 
Expenditures 
Attributable 
Expenditures 
(Standard Error)($) 
 Percent of 
Mean 
Expenditures 
Attributable 
Expenditures 
(Standard Error)($) 
 Percent of 
Mean 
Expenditures 
Attributable 
Expenditures 
(Standard Error)($) 
 
Percent of Mean 
Expenditures 
Breast 9,366 
(183) 
*** 44.7 3,994 
(315) 
*** 18.3 7,536 
(261) 
*** 36.3 12,393 
(685) 
*** 43.1 
Cervical 4,754 
(318) 
*** 25.2 −49 
(478) 
 N/A 2,922 
(426) 
*** 20.2 5,922 
(1,149) 
*** 25.7 
Colorectal 9,819 
(291) 
*** 35.9 9,788 
(434) 
*** 36,8 8,349 
(392) 
*** 34.2 16,737 
(1,133) 
*** 41.6 
Lung 13,440 
(232) 
*** 41.2 11,867 
(383) 
*** 26.8 12,351 
(327) 
*** 39.5 29,209 
(873) 
*** 51.5 
Melanoma 5,639 
(686) 
*** 26.7 1,767 
(1,239) 
 N/A −416 
(1,070) 
 N/A 4,029 
(1,572) 
* 18.1 
Prostate 2,508 
(382) 
*** 14.0 −194 
(587) 
 N/A 4,766 
(616) 
*** 25.7 12,089 
(1,893) 
*** 34.4 
***Significantly different from 0 at p  < 0.001; *Significantly different from 0 at p  < 0.05; N/A Percentage of mean expenditures not reported 
because per -capita cost estimate is not significant  at P < 0.05. 
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Note: Total costs are not  reported for cervical,  melanoma, and prostate in Illinois and melanoma in 
Louisiana because per -capita cost estimate is not significant at P  < 0.05.  
Figure 1  Total Annualized Cancer Attributable Expenditures for Medicaid -Only Beneficiaries by State 
and Cancer Site,  Age >  18 
 
Discussion 
Total annualized Medicaid expenditures 
attributable to the six cancers combined in the 
Medicaid-only adult population, reported in 2003 
dollars, were $84.0 million in Georgia, $79.7 
million in Illinois, $51.4 million in Louisiana, and 
$29.4 million in Maine. These cancer costs account 
for about 2% of total annual Medicaid 
expenditures for the Medicaid-only adult 
population in all of the study states except Illinois, 
where they were about 1% of expenditures.  
Variation among states in Medicaid expenditures 
attributable to the six cancers reflects differences 
in Medicaid population sizes, cancer prevalence, 
and per-capita cancer costs. Variation in the 
prevalence of cancer in the Medicaid-only 
population may reflect differences between states 
in age distribution, other sociodemographics, and 
health characteristics, due to both general 
population differences and differences in Medicaid 
eligibility requirements. Per-capita cost differences 
among states may reflect differences in cancer 
stage at diagnosis, phase of care, practice patterns, 
Medicaid benefits, Medicaid program management, 
and Medicaid payment rates. State expenditure 
differences are likely driven by a complex set of 
factors. These analyses do not identify the extent 
to which variation in expenditure patterns among 
states is explained by differences in patient clinical 
characteristics, Medicaid payment rates, other 
Medicaid program policies, or provider practices. 
Further study is needed to understand the sources 
of state expenditure differences, as well as the 
implications of these differences for 
cost-effectiveness and accessibility of care.  
The cost estimates represent annual Medicaid 
expenditures attributable to these six cancers. 
Medicaid beneficiaries may have periods of private 
insurance coverage or uninsurance during the time 
they receive cancer treatment [21]. Because of 
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these coverage discontinuities, these estimates 
likely do not reflect the full cost of cancer 
treatment in the Medicaid population. However, 
they do accurately capture the portion of 
expenditures borne by Medicaid. Our estimates 
include both incident and prevalent cases, so they 
are lower than the average annual cost of a person 
in active treatment. Furthermore, they reflect costs 
per year, not total treatment costs per diagnosed 
case. 
Unlike many other cost of illness studies, this 
study does not rely on reporting of specific 
procedure or diagnosis codes to identify cancer 
treatments. Rather, regression adjustment was used 
to compare expenditures for Medicaid-only 
eligible beneficiaries with the six study cancers to 
other Medicaid-only eligible beneficiaries, 
controlling for sociodemographic characteristics 
and comorbidities. Our estimates are not affected 
by inaccuracies in reporting procedure and 
diagnosis codes to identify claims for 
cancer-related expenditures.  
After adjusting for sociodemographic factors 
and comorbidities, we found that most medical 
expenditures among Medicaid-only beneficiaries 
with the six cancers were not attributable to the 
cancers. The relatively low proportion of 
expenditures attributable to the cancers reflects the 
high prevalence of comorbidities among Medicaid 
beneficiaries with the study cancers. The high rate 
of comorbidities in the population with cancer 
reflects the high burden of illness in the Medicaid 
population generally [22] and the older age 
distribution of the Medicaid-only population with 
cancer, which has a mean age of 51 to 55 years 
depending on the state, compared to 34 to 36 years 
for Medicaid-only beneficiaries without cancer. 
Analyses of Medical Expenditure Panel Survey 
data showed rates of hypertension among Medicaid 
beneficiaries age 45 to 64 in the four study states 
ranged from 41% to 48%, about four times higher 
than rates for those age 18-44 [23]. The somewhat 
higher rates in our analyses likely reflect 
differences in how diseases were identified, as well 
as higher rates of comorbidities among those with 
cancer compared with those without cancer [13]. It 
is important to account for comorbidities when 
estimating costs attributable to cancer, given both 
the higher rate of comorbidities among those with 
cancer compared with those without cancer, and 
the higher total costs among cancer patients with 
comorbidities [13, 24]. 
The study population included individuals in 
varying phases of cancer care, ranging from initial 
treatment to continuing care to terminal care. The 
share of annual medical expenditures attributable 
to cancer may vary depending on patients’ phase of 
care. We were not able to control for treatment 
phase in these claims-based analyses. The share of 
medical expenditures attributable to cancer would 
likely be higher for those in active treatment or 
receiving end-of-life care. Patients with breast or 
prostate cancers are likely to survive longer after 
diagnosis, and therefore a greater proportion of 
patients in our data with these cancers will have 
completed treatment and be in a less expensive 
phase of care. By contrast, patients with lung or 
colorectal cancer have shorter survival [25]; 
therefore, more of these patients in our study are 
likely to be in active treatment or in end-of-life 
care, which are more costly [7, 13, 26]. A previous 
study reported that a high proportion of medical 
costs for colorectal cancer patients was attributable 
to cancer during the initial and terminal phases of 
care, whereas cancer-related costs accounted for a 
lower proportion of costs during the period 
between these phases
 
[7]. The inclusion of cases 
that were no longer in active treatment likely 
explains the attributable cost estimates that were 
not significantly different from 0.  
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Our findings that a relatively small proportion of 
medical expenditures are attributable to cancer 
may not extend to other populations. It is likely 
that the prevalence of comorbidities is higher 
among Medicaid beneficiaries with cancer than in 
the general population because of the Medicaid 
population’s generally poorer health status. 
According to statistics derived by the researchers 
from the Current Population Survey
 
[27], 
non-elderly adults covered by Medicaid are 3.8 
times more likely than those not covered by 
Medicaid to report being in fair or poor health.  
Total attributable costs for each cancer reflect 
both the attributable per-capita costs and the 
number of Medicaid beneficiaries with that cancer. 
High total attributable costs for lung cancer reflect 
its high per-capita attributable cost and its 
relatively high prevalence in the Medicaid 
population. Low total attributable expenditures for 
cervical, melanoma, and prostate cancers reflect 
the lower prevalence of these cancers and their 
lower per-capita attributable costs. 
This study has several limitations. First, these 
estimates, which used data from 2000–2003, 
understate Medicaid costs today. Taking into 
account inflation, costs in 2011 would be 20 
percent higher than our 2003 cost estimates. These 
inflation-adjusted expenditure estimates do not 
account for increases in the number of cancer 
treatments or cost increases for cancer treatments 
that differ from general inflation [12] and, 
therefore, likely understate current expenditures. 
However, cancer spending as a percent of overall 
medical expenditures and expenditures by payer 
has remained constant over the past two decades 
[2]. This suggests that our estimates of the burden 
of cancer expenditures for the Medicaid program 
are not seriously biased by using older data. 
Second, estimates may be biased by differences 
in the identification of comorbidities. People with 
cancer may be more likely to have comorbid 
conditions diagnosed because they see a doctor 
more often. Higher rates of diagnosing 
comorbidities in the study cancer population would 
lead to an underestimate of cancer-attributable 
costs.  
Third, these analyses are based on data from 
only four states, which may not be representative 
of the nation. Indeed, the substantial variation 
among states in cancer prevalence and per-capita 
expenditures attributable to cancer in our analyses 
makes it difficult to extrapolate findings from 
state-to- state.  
Fourth, beneficiaries with the study cancers 
(other than lung cancer) were enrolled in Medicaid 
longer than other beneficiaries. We adjusted for 
differences in length of enrollment by using 
annualized expenditures as the dependent variable 
and weighted our analyses by months of 
enrollment. Annualization, combined with 
weighting by length of enrollment, is commonly 
used in health care expenditure analyses to account 
for differences in observation periods [17, 28]. 
Annualization may overstate expected annual costs 
for individuals with less than a full year of 
enrollment, particularly those who die before being 
enrolled for a full year.  
However, weighting by length of enrollment 
gives less importance in the analyses to individuals 
with brief periods of enrollment. We examined 
potential distortions due to annualization by 
re-estimating expenditures, excluding individuals 
with a date of death reported in the MAX data. 
(This was not possible for Maine, which did not 
report date of death in MAX data.) Excluding 
individuals that die reduces estimates of the costs 
attributable to the study cancers by 10 to 20 
percent, which is expected given that end-of-life is 
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a more costly phase of cancer treatment [7]. Our 
study provides an important assessment of the 
economic burden of six of the cancers most 
prevalent in Medicaid programs in four states. 
Estimates of the costs of cancer care for 
Medicaid-eligible patients are critical to 
understanding the impact of cancer on state and 
federal budgets and to allocating resources for 
cancer prevention and treatment. Although 
Medicaid expenditures attributable to cancer are 
small compared to chronic diseases such as 
hypertension and diabetes [23] cancer expenditures 
have grown more rapidly in Medicaid than in 
Medicare and privately insured populations [2]. 
The substantial increase in the adult Medicaid 
population due to the Medicaid coverage 
expansion under the ACA will reinforce this trend.  
Understanding the anticipated cost burden on 
Medicaid programs may create incentives for 
states to increase investment in cancer prevention 
initiatives, such as tobacco control initiatives or 
Medicaid coverage of smoking cessation programs.  
The ACA also creates opportunities for 
screening and earlier detection of cancer that could 
reduce per-capita treatment expenditures for 
people diagnosed with cancer. Previous studies 
have found that large percentages of the Medicaid 
population with breast or cervical cancer first 
enrolled in Medicaid shortly before or soon after 
their cancer diagnosis [29, 30]. Those enrolling in 
Medicaid around the time of cancer diagnosis have 
more advanced stage disease, including metastatic 
cancer, than those continuously enrolled before 
diagnosis
 
[29,30]. These factors contribute to 
higher cancer-attributable costs for Medicaid 
programs. If the ACA extends Medicaid coverage 
to large numbers of low-income adults so that 
fewer people first enroll when they are diagnosed 
with cancer, there should be more opportunities for 
screening and earlier detection, resulting in lower 
per-capita treatment costs and higher survival 
rates.  
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